Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-09-14
Rabinowitz Matthew Files Natera (NTRA) Form 4 - September 14, 2026
Rabinowitz Matthew sold 102.0K NTRA shares worth $34.8M in this Form 4 filing, reported to the SEC on 2026-09-14.
- Insider
- Rabinowitz Matthew
- Issuer
- Natera, Inc. NTRA · NASDAQ
- Filed
- Period
- 2026-09-14
- Accession
- 0001646382-26-000021
- Source
- Official filing on sec.gov ↗
Transactions (29)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Rabinowitz Matthew | 2026-09-15 | Sell | 1.5K | $339.24 | $502.4K | Direct |
| Rabinowitz Matthew | 2026-09-15 | Sell | 2.5K | $340.25 | $867.3K | Direct |
| Rabinowitz Matthew | 2026-09-15 | Sell | 1.8K | $341.41 | $619.0K | Direct |
| Rabinowitz Matthew | 2026-09-15 | Sell | 2.0K | $342.18 | $669.3K | Direct |
| Rabinowitz Matthew | 2026-09-15 | Sell | 2.2K | $343.56 | $769.6K | Direct |
| Rabinowitz Matthew | 2026-09-15 | Sell | 5.8K | $344.49 | $2.0M | Direct |
| Rabinowitz Matthew | 2026-09-15 | Sell | 2.7K | $345.38 | $932.5K | Direct |
| Rabinowitz Matthew | 2026-09-15 | Sell | 1.1K | $346.68 | $389.0K | Direct |
| Rabinowitz Matthew | 2026-09-15 | Sell | 2.7K | $347.81 | $939.1K | Direct |
| Rabinowitz Matthew | 2026-09-15 | Sell | 8.1K | $348.65 | $2.8M | Direct |
| Rabinowitz Matthew | 2026-09-15 | Sell | 4.2K | $349.51 | $1.5M | Direct |
| Rabinowitz Matthew | 2026-09-15 | Sell | 14.5K | $350.81 | $5.1M | Direct |
| Rabinowitz Matthew | 2026-09-15 | Sell | 800 | $351.25 | $281.0K | Direct |
| Rabinowitz Matthew | 2026-09-15 | Sell | 2.0K | $350.01 | $700.0K | Indirect |
| Rabinowitz Matthew | 2026-09-14 | Sell | 1.5K | $328.09 | $504.3K | Direct |
| Rabinowitz Matthew | 2026-09-14 | Sell | 4.1K | $342.51 | $1.4M | Direct |
| Rabinowitz Matthew | 2026-09-14 | Sell | 6.0K | $329.12 | $2.0M | Direct |
| Rabinowitz Matthew | 2026-09-14 | Sell | 6.2K | $330.05 | $2.0M | Direct |
| Rabinowitz Matthew | 2026-09-14 | Sell | 3.5K | $330.98 | $1.2M | Direct |
| Rabinowitz Matthew | 2026-09-14 | Sell | 1.0K | $332.02 | $332.0K | Direct |
| Rabinowitz Matthew | 2026-09-14 | Sell | 2.2K | $333.07 | $748.1K | Direct |
| Rabinowitz Matthew | 2026-09-14 | Sell | 2.8K | $334.24 | $941.9K | Direct |
| Rabinowitz Matthew | 2026-09-14 | Sell | 3.8K | $335.18 | $1.3M | Direct |
| Rabinowitz Matthew | 2026-09-14 | Sell | 8.5K | $336.27 | $2.8M | Direct |
| Rabinowitz Matthew | 2026-09-14 | Sell | 2.2K | $337.17 | $744.1K | Direct |
| Rabinowitz Matthew | 2026-09-14 | Sell | 1.4K | $338.30 | $473.6K | Direct |
| Rabinowitz Matthew | 2026-09-14 | Sell | 2.1K | $339.37 | $712.7K | Direct |
| Rabinowitz Matthew | 2026-09-14 | Sell | 2.0K | $340.31 | $680.6K | Direct |
| Rabinowitz Matthew | 2026-09-14 | Sell | 2.7K | $341.35 | $921.6K | Direct |
| Net change | −102.0K | −$34.8M | ||||
About Natera, Inc.
Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use. The company focuses on oncology, women’s health, and organ health, using proprietary molecular assays and bioinformatics to help detect and monitor genetic conditions and disease-related changes from small blood samples. Its current product portfolio includes prenatal screening, carrier screening, cancer monitoring, and transplant rejection assessment tests, serving physicians, hospitals, health systems, transplant centers, and biopharma partners. Natera’s tests are used to support areas such as reproductive health, cancer residual disease monitoring, recurrence surveillance, and organ transplant management. Headquartered in Austin, Texas, Natera plays an important role in the growing precision medicine market by providing non-invasive diagnostic tools that help inform clinical decision-making across multiple medical specialties.
Track NTRA insider activity
Get alerted when Natera, Inc. executives buy or sell their shares.